CML-277: Efficacy of Bosutinib in Imatinib-Resistant vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study
Year: 2020
Type: conference-abstract
Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of Bologna, Universitätsklinikum Aachen, RWTH Aachen University, Weill Cornell Medicine, University of Milano-Bicocca, Institut Paoli-Calmettes, Pfizer (Spain), Pfizer (United States), Jena University Hospital
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: bosutinib, chronic myeloid leukemia, chronic phase, imatinib resistance, dasatinib resistance, nilotinib resistance, tyrosine kinase inhibitor intolerance, complete cytogenetic response, complete molecular response, treatment discontinuation, adverse events, Philadelphia chromosome-positive leukemia, long-term follow-up, dose intensity, treatment duration, progression-free survival
Open Access status: closed
OpenAlex ID: W2985522202
